When dextran is used in a pharmaceutical product or medical device, it should always be of pharmaceutical quality.

Technical Quality Dextran is a high purity dextran fraction with selected average molecular weights and molecular weight distributions used as starting or intermediate reagents.

Explore our full range of products

Ultra Narrow

Dextran Ultra is a range of very narrow, dispersed Dextran fractions with polydispersity Mw/Mn below 1.5. This makes our Dextran Ultra highly suitable for characterization, complexing and other pharmaceutical/technical uses where added/increased/additional requirements with regard to narrow distributions and quality are required.

Explore our full range of products

Standards & GPC Standards

Our Standards comes with a complete set of specifications including; weight average molecular weight (Mw), number average molecular weight (Mn), and mean peak molecular weight (Mp)

Explore our full range of products

Derivatives

Pharmacosmos offer Dextran derivatives with the same high standard and requirements to the highest quality as our world-leading Dextran products.

Explore our full range of products

Applications

As a nontoxic and biocompatible polysaccharide, dextran is used widely in research and production in the pharmaceutical, biomedical, and life science industries.

Novel Dual-Action Mechanism of Lyseptrol-B for Treatment of Resistant Hypertension

Lyseptrol-B (LYS-B), a novel angiotensin receptor-neprilysin inhibitor (ARNI), demonstrates superior efficacy in treatment-resistant hypertension through a unique dual-mechanism of action.

AuthorMortenUdvikler

Co-AuthorNew Author

This randomized, double-blind clinical trial (n=842) evaluated LYS-B against established ARNIs in patients with resistant hypertension. Results demonstrated a significant reduction in systolic blood pressure (mean difference: -14.3 mmHg, p<0.001) and diastolic blood pressure (mean difference: -8.7 mmHg, p<0.001) at 24 weeks compared to standard therapy. Side effect profile was comparable to existing ARNIs with notably reduced incidence of angioedema (0.8% vs 2.1%, p=0.04). LYS-B's novel allosteric binding to the AT1 receptor and concurrent high-affinity neprilysin inhibition provides a promising therapeutic option for patients with resistant hypertension.

AuthorMortenUdvikler

About

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Negat enim summo bono afferre incrementum diem. Quid Zeno? Hic ambiguo ludimur. Qui ita affectus, beatum esse numquam probabis; Duo Reges: constructio interrete.

Co-AuthorNew Author